The purpose of this legislation, known as the Next Generation Medicines Act of 2026, is to update the rules regarding certain drugs, specifically engineered cyclic peptides, within the Drug Price Negotiation Program. The main goal is to allow for better negotiation of prices for these specialized drugs, which can lead to lower costs for consumers and healthcare providers. Key provisions of the legislation include a change in the duration of exclusivity for engineered cyclic peptides. Previously, the exclusivity period was set at seven years, but this bill extends it to eleven years.